Your browser doesn't support javascript.
loading
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Rasmussen, Daniel Guldager Kring; Anstee, Quentin M; Torstenson, Richard; Golding, Bruno; Patterson, Scott D; Brass, Clifford; Thakker, Paresh; Harrison, Stephen; Billin, Andrew N; Schuppan, Detlef; Dufour, Jean-François; Andersson, Anneli; Wigley, Ioan; Shumbayawonda, Elizabeth; Dennis, Andrea; Schoelch, Corinna; Ratziu, Vlad; Yunis, Carla; Bossuyt, Patrick; Karsdal, Morten Asser.
Afiliación
  • Rasmussen DGK; Nordic Bioscience, Denmark. Electronic address: dgr@nordicbio.com.
  • Anstee QM; Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom; Newcastle NIHR Biomedical Research Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Torstenson R; Astrazeneca, Regulatory Affairs, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Golding B; Roche Diagnostics International, Rotkreuz, Switzerland.
  • Patterson SD; Gilead Sciences, Inc, Foster City, California, USA.
  • Brass C; Novartis, East Hanover, NJ 07936, USA.
  • Thakker P; Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA.
  • Harrison S; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Billin AN; Gilead Sciences, Inc, Foster City, California, USA.
  • Schuppan D; Institute of Translational Immunology and Research Center for Immune Therapy, Mainz University Medical Center, 55131, Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Dufour JF; Centre for Digestive Diseases, Lausanne, Switzerland.
  • Andersson A; Perspectum, Oxford, OX4 2LL, United Kingdom.
  • Wigley I; Perspectum, Oxford, OX4 2LL, United Kingdom.
  • Shumbayawonda E; Perspectum, Oxford, OX4 2LL, United Kingdom.
  • Dennis A; Perspectum, Oxford, OX4 2LL, United Kingdom.
  • Schoelch C; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
  • Ratziu V; Sorbonne University, Paris, France; Pitié-Salpêtrière Hospital, Paris, France.
  • Yunis C; Global Product Development, Internal Medicine and Hospital, Pfizer Inc, Florida, USA.
  • Bossuyt P; Department of Epidemiology and Data Science, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands.
  • Karsdal MA; Nordic Bioscience, Denmark.
J Hepatol ; 78(4): 852-865, 2023 04.
Article en En | MEDLINE | ID: mdl-36526000
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article